MacroGenics Q4 2021 Earnings Report
Key Takeaways
MacroGenics reported its 2021 financial results, with total revenue of $77.4 million and a net loss of $202.1 million. The company's cash, cash equivalents, and marketable securities totaled $243.6 million as of December 31, 2021, which is expected to fund operations through 2023.
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab in coming weeks.
Prioritizing MGD024 as lead CD3-based DART molecule targeting CD123 and discontinuing development of flotetuzumab.
Presented encouraging preclinical combinatorial anti-tumor activity with MGD024 at ASH in December.
Plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the design of a potential registration-directed study of MGC018 in patients with metastatic castration-resistant prostate cancer (mCRPC).
MacroGenics
MacroGenics
MacroGenics Revenue by Segment
Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities as of December 31, 2021, plus anticipated and potential collaboration payments, and product revenues should enable it to fund its operations through 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income